Brief: HLS Therapeutics Reports Q3 Loss Per Share Of $0.72
Nov 15 (Reuters) - HLS Therapeutics Inc HLS.V :
* HLS THERAPEUTICS ANNOUNCES Q3 2018 FINANCIAL RESULTS
* QTRLY LOSS PER SHARE $0.72
* Q3 LOSS PER SHARE $0.72
* ESTABLISHMENT OF A DIVIDEND POLICY PROVIDING FOR PAYMENT
OF
QUARTERLY DIVIDENDS OF C$0.05 PER COMMON SHARE
* QTRLY REVENUE $15.3 MILLION VERSUS $20.3 MILLION
* AS OF SEPT 30, CO HAD CASH AND CASH EQUIVALENTS OF $9.9
MILLION
VERSUS $36.2 MILLION AT DEC 31, 2017
Source text for Eikon: ID:nCNW7JlF6a
Further company coverage: HLS.V
(Reuters.Briefs@thomsonreuters.com)
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease